The same finding was observed in the MCF10A-derived model of breast cancer progression, whereby both the invasive (CA1ACL1 and CA1DCL1) and the DCIS.com cell variants co-expressed higher levels of EphB2, EFNB1, and EFNB2 than the benign parental MCF10A cell line. This evidence concerns the gene EPHB2 and ductal breast carcinoma in situ.